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Abstract
Yeasts are regarded as the first microorganisms used by humans to process food and alcoholic beverages. The
technology developed out of these ancient processes has been the basis for modern industrial biotechnology.
Yeast biotechnology has gained great interest again in the last decades. Joining the potentials of genomics, metabolic
engineering, systems and synthetic biology enables the production of numerous valuable products of primary and
secondary metabolism, technical enzymes and biopharmaceutical proteins. An overview of emerging and established
substrates and products of yeast biotechnology is provided and discussed in the light of the recent literature.
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Background
The use of yeast for food processing and fermentation
of alcoholic beverages is traditionally marked as the
primary inventive step of biotechnology, dating back
several millennia. The discovery of microbial metabolic
activities from the 19th century onward initiated the
target-oriented development of yeast bioprocesses which
were the prototype of modern biotechnological processes.
A major hallmark was the development of the “Zulaufver-
fahren” for efficient baker’s yeast production [1]. Today
this process is employed under the term “fed-batch” to
avoid overflow metabolism in the majority of industrial
bioproductions. Efficient fermentative processes developed
for ethanol production served as a model for the pro-
duction of different metabolic products from yeasts,
filamentous fungi and bacteria.
Bacteria and filamentous fungi have taken over the
lead role in the development of bioprocesses around
mid of the 20th century [2]. However since then novel
developments of recombinant protein production, meta-
bolic engineering, and systems and synthetic biology,
paired by the demand for many products which can be
synthesized by yeasts enable a plethora of new applications
of yeasts in biotechnology. We see three major fields of
application for yeasts in modern biotechnology: produc-
tion of metabolites, production of recombinant proteins,
and in vivo biotransformations.
Traditionally “yeast” denotes Saccharomyces cerevisiae
and its close relatives, used for alcoholic fermentation
and baking. However today about 1500 yeast species
have been identified (a variable number due to current
reclassifications). Biotechnologists have summarized all
non-S. cerevisiae yeasts which they use as “non-conven-
tional” yeasts. What unifies them is a lower degree of
fermentative overflow metabolism [3] and a rather short
history of genetic and biological characterization. The
lifestyle of S. cerevisiae is characterized by flourishing in
extremely high sugar concentrations – disposing most of
it as the fermentative by-product ethanol. Most natural
habitats however do not provide such extreme substrate
conditions so that most non-conventional yeasts provide
alternative metabolic routes for substrate utilization and
product formation, and different regulatory patterns. A
few species of major interest are Pichia pastoris (syn.
Komagataella pastoris), Hansenula polymorpha (syn.
Ogataea parapolymorpha), Yarrowia lipolytica, Pichia
stipitis (syn. Scheffersomyces stipitis), or Kluyveromyces
marxianus.
The classical carbon substrates for yeast processes
are glucose or sucrose, derived mainly from corn starch
and cane sugar. Extrapolating the successful expansion of
industrial biotechnology, and most importantly considering
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the food requirements of mankind lets us envisage a short-
age of these classical substrates, driving research towards
the utilization of alternative carbon sources. Lignocellulose
hydrolysate constitutes such an abundant carbon source,
requiring yeasts that can utilize xylose and arabinose
(the major constituents of hemicellulose). These are
either natural pentose assimilating yeasts like e.g. Pichia
stipitis [4] or Hansenula polymorpha [5], or S. cerevisiae
strains with engineered pentose utilization pathways
[6]. Alternatively, glycerol as an abundant by-product
of biodiesel production is explored as a substrate for
yeast processes. While also S. cerevisiae can utilize glycerol,
the uptake and assimilation is much higher in other
yeasts like Pachysolen tannophilus [7], Y. lipolytica [8,9],
or P. pastoris [10].
Different substrates and products of yeast biotechnol-
ogy are summarized in Figure 1. In the following, the
main current applications of yeasts are discussed.
Yeasts as platforms for metabolite production
Due to the foreseeable limitation of mineral oil resources
the interest in biotechnological production of chemicals
by microbial metabolic activities is ever increasing. While
the first wave of metabolite production processes used
natural producers of desired molecules (e.g. production
of astaxanthin by Phaffia rhodozyma (syn. Xanthophyllo-
myces dendrorhous) or production of riboflavin by Pichia
guilliermondii), current concepts aim at engineering a few
platform strains for the production of many chemicals.
Several physiological features predestine yeasts as such
a platform [11]: high substrate uptake rates, potentially
high metabolic rates, robustness against stressful process
conditions. Additionally, there is also a revival in engineer-
ing of natural production hosts for improved productivity
as the increasing availability of yeast genome sequences
enables better understanding and relief of rate-limiting
steps based on the results of Omics data and metabolic
modelling.
Ethanol made by yeast is by far the largest biotech
product [12]. The development of more efficient and
robust strains using different substrates has been a major
driving force for the development of the yeast platform.
However, ethanol as a biofuel suffers from a low substrate
yield and a rather low energy content, so that the pro-
duction of other alcohols like butanol or isobutanol is
attempted today [13-16].
Figure 1 Substrates and products of yeast bioprocesses. Main carbon sources employed in yeast bioprocesses are derived from (A) corn
starch, (B) cane or beet sugar, (C) lignocellulose (corn stover, straw, wood etc.) and (D) crude glycerol from biodiesel production. Different native
and engineered yeast strains convert the substrate to products of (E) primary or (F) secondary metabolism, or (G) recombinant proteins. Whole
cell biocatalysis is a special case where (H) a complex substrate is biochemically transformed to (I) a product by the metabolic activity of yeast
cells. Chemical structures are illustrative images only.
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Several short chain organic acids are valued precursor
chemicals. Production of the free acid requires low pH
of the culture broth, so that the acid tolerance of yeasts
is a valuable feature. Low pH lactic acid production has
been achieved in S. cerevisiae [17], P. stipitis [18], Candida
boidinii [19] and Candida sorenensis [20] and is reaching
industrial scale. Succinic acid production with engineered
S. cerevisiae is employed in a process announced to reach
30,000 t/y scale in 2015 [21].
Efficient pathways for production of phenolic substances
such as flavonoids [22] and stilbenoids [23] have been
developed but still need further increase of productivity
and yield.
Isoprenoids are a universal class of molecules all based
on the same building blocks. This universality enables to
design novel pathways in yeasts, using the native core
structures with specific conversions carried out by heterol-
ogous pathways. Thereby, often recombinant genes from
different species are combined to obtain the intended
variety. Isoprenoids encompass more than 40,000 plant
secondary metabolites, a number of them with pharma-
ceutical activity. Recently yeast based production of the
antimalaria agent artemisinin reached commercial pro-
duction [24]. Isoprenoids produced with recombinant
yeast have also been proposed as biobased jet fuel [25].
Polyketides are complex biomolecules mainly of bacterial
or fungal origin. Recombinant expression of polyketide
synthases in yeasts enables the study of their complex
function [26] and the development of heterologous produc-
tion strains [27,28]. The heterologous production of syn-
thetic penicillins in yeasts has been suggested as well [29].
Recombinant protein production in yeasts
S. cerevisiae has been the first yeast employed for pro-
duction of heterologous proteins [30]. In the early 1980s
this was the only yeast species with significant molecular
genetic characterization which explains its wide commer-
cial use in the following years for production of human
insulin and hepatitis B surface antigen. It has turned
out however that other yeasts are more efficient in the
production of many recombinant proteins [31-33]. A
current literature survey indicates that most work on
recombinant protein production in yeasts is performed
with P. pastoris and H. polymorpha, followed by S.
cerevisiae and Y. lipolytica. In 2009, about 20% of the
biopharmaceutical products approved in U.S.A. and
Europe were produced in S. cerevisiae [34]. Other yeast
platforms play an important role in clinical studies
and have begun to enter the biopharma market in the
recent years.
Secretion of recombinant proteins to the culture super-
natant constitutes a major bottleneck of yeast production
hosts [35], favouring some non-conventional yeasts over S.
cerevisiae [32,33]. A genomic comparison of the secretory
pathway of 8 yeast species indicates that S. cerevisiae and
its close relatives have lost some functions of secretory
protein quality control [36]. Engineering of folding and
secretion related genes is a valuable strategy to enhance
the secretory capacity of yeasts [35,37-39], however the
comparison to mammalian cells like Chinese hamster
ovary cells shows that there is still a lot of room for
improvement [40].
Systems biology has strongly contributed to our current
understanding of limitations of protein production [41].
Genome scale transcriptomics and proteomics revealed
physiological reactions to protein overproduction [42].
Overexpression has a severe impact on primary metab-
olism reflecting a higher demand for energy and reducing
equivalents [43,44] and free amino acids [45,46]. Meta-
bolic engineering may further channel the flux towards
required precursers (own unpublished data), and may also
contribute to enhanced protein secretion by providing
sufficient cofactors, e.g. heme [47].
Whole cell biocatalysis
To differentiate from microbial metabolite production,
whole cell biocatalysis may be defined as the conversion
of organic compounds by enzymatic activities of life cells.
The main advantages compared to classical biocatalysis
are the cheap production of the required enzymatic setup,
and/or the use of the cellular metabolism for cofactor
regeneration. Recombinant yeast whole cell biocatalysts
have been developed for the conversion of cephalosporins
[48] and steroids [49], and the asymmetric reduction of
α-keto esters [50]. Whole cell biocatalysts usually exert
their activity intracellularly. However also secreted enzymes
may act in in vivo biotransformations. E.g. D-tagatose has
been produced from D-lactose by secretory production
of bacterial β-D-galactosidase and L-arabinose isomerase
[51]. Yeast surface display of lipase enabled the whole cell
based production of phospholipids and fatty acid methyl
esters [52].
Conclusions
Recent research has generated exciting new developments
of products and bioprocesses using yeasts. Common pat-
terns of successful yeast based processes are the efficient
use of substrate, and a closed energy and redox balance
where metabolic engineering may serve to meet the extra
demand of product formation. Engineering the protein
secretory pathway solves specific problems in overproduc-
tion of recombinant proteins.
To provide a forum for scientific discourse, Microbial
Cell Factories has initiated a thematic series on Yeast
Biotechnology [53]. This virtual series will continue to
compile the most relevant papers in yeast research
published in Microbial Cell Factories, to serve research
in this field for the benefit of mankind.
Mattanovich et al. Microbial Cell Factories 2014, 13:34 Page 3 of 5
http://www.microbialcellfactories.com/content/13/1/34
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors have contributed equally to this commentary, and all have read
and approved the final manuscript.
Acknowledgements
The authors’ research on yeast biotechnology is funded by the Federal
Ministry of Economy, Family and Youth (BMWFJ), the Federal Ministry of
Traffic, Innovation and Technology (bmvit), the Styrian Business Promotion
Agency SFG, the Standortagentur Tirol and ZIT – Technology Agency of
the City of Vienna through the COMET-Funding Program managed by the
Austrian Research Promotion Agency FFG. Additional support by the program
“Intelligente Produktion” of FFG, project “Lignoraffinerie” and by the Austrian
Science Fund (FWF): Doctoral Program BioToP—Biomolecular Technology of
Proteins (FWF W1224) is acknowledged.
Received: 31 December 2013 Accepted: 15 February 2014
Published: 6 March 2014
References
1. Internatl. Yeast Co. Ltd: Verfahren zur Herstellung von Hefe nach dem
Zulaufverfahren. ; 1933. German Patent DE583760.
2. Porro D, Gasser B, Fossati T, Maurer M, Branduardi P, Sauer M, Mattanovich
D: Production of recombinant proteins and metabolites in yeasts: when
are these systems better than bacterial production systems? Appl
Microbiol Biotechnol 2011, 89:939–948.
3. Rozpędowska E, Hellborg L, Ishchuk OP, Orhan F, Galafassi S, Merico A,
Woolfit M, Compagno C, Piskur J: Parallel evolution of the make-
accumulate-consume strategy in Saccharomyces and Dekkera yeasts.
Nat Commun 2011, 2:302.
4. Toivola A, Yarrow D, van den Bosch E, van Dijken JP, Scheffers WA:
Alcoholic fermentation of d-Xylose by yeasts. Appl Environ Microbiol 1984,
47:1221–1223.
5. Ryabova OB, Chmil OM, Sibirny AA: Xylose and cellobiose fermentation to
ethanol by the thermotolerant methylotrophic yeast Hansenula
polymorpha. FEMS Yeast Res 2003, 4:157–164.
6. Walfridsson M, Hallborn J, Penttilä M, Keränen S, Hahn-Hägerdal B:
Xylose-metabolizing Saccharomyces cerevisiae strains overexpressing
the TKL1 and TAL1 genes encoding the pentose phosphate pathway
enzymes transketolase and transaldolase. Appl Environ Microbiol 1995,
61:4184–4190.
7. Liu X, Mortensen UH, Workman M: Expression and functional studies of
genes involved in transport and metabolism of glycerol in Pachysolen
tannophilus. Microb Cell Fact 2013, 12:27.
8. Workman M, Holt P, Thykaer J: Comparing cellular performance of
Yarrowia lipolytica during growth on glucose and glycerol in submerged
cultivations. AMB Express 2013, 3:58.
9. Celińska E, Grajek W: A novel multigene expression construct for
modification of glycerol metabolism in Yarrowia lipolytica. Microb Cell
Fact 2013, 12:102.
10. Mattanovich D, Graf A, Stadlmann J, Dragosits M, Redl A, Maurer M,
Kleinheinz M, Sauer M, Altmann F, Gasser B: Genome, secretome and
glucose transport highlight unique features of the protein production
host Pichia pastoris. Microb Cell Fact 2009, 8:29.
11. Nielsen J, Larsson C, van Maris A, Pronk J: Metabolic engineering of yeast for
production of fuels and chemicals. Curr Opin Biotechnol 2013, 24:398–404.
12. Mussatto SI, Dragone G, Guimarães PM, Silva JP, Carneiro LM, Roberto IC,
Vicente A, Domingues L, Teixeira JA: Technological trends, global market,
and challenges of bio-ethanol production. Biotechnol Adv 2010, 28:817–830.
13. Steen EJ, Chan R, Prasad N, Myers S, Petzold CJ, Redding A, Ouellet M,
Keasling JD: Metabolic engineering of Saccharomyces cerevisiae for the
production of n-butanol. Microb Cell Fact 2008, 7:36.
14. Lan EI, Liao JC: Microbial synthesis of n-butanol, isobutanol, and other
higher alcohols from diverse resources. Bioresour Technol 2013, 135:339–349.
15. Branduardi P, Longo V, Berterame NM, Rossi G, Porro D: A novel pathway
to produce butanol and isobutanol in Saccharomyces cerevisiae.
Biotechnol Biofuels 2013, 6:68.
16. Matsuda F, Ishii J, Kondo T, Ida K, Tezuka H, Kondo A: Increased isobutanol
production in Saccharomyces cerevisiae by eliminating competing
pathways and resolving cofactor imbalance. Microb Cell Fact 2013, 12:119.
17. Porro D, Bianchi MM, Brambilla L, Menghini R, Bolzani D, Carrera V, Lievense
J, Liu CL, Ranzi BM, Frontali L, Alberghina L: Replacement of a metabolic
pathway for large-scale production of lactic acid from engineered yeasts.
Appl Environ Microbiol 1999, 65:4211–4215.
18. Ilmén M, Koivuranta K, Ruohonen L, Suominen P, Penttilä M: Efficient
production of L-lactic acid from xylose by Pichia stipitis. Appl Environ
Microbiol 2007, 73:117–123.
19. Osawa F, Fujii T, Nishida T, Tada N, Ohnishi T, Kobayashi O, Komeda T,
Yoshida S: Efficient production of L-lactic acid by Crabtree-negative yeast
Candida boidinii. Yeast 2009, 26:485–496.
20. Ilmén M, Koivuranta K, Ruohonen L, Rajgarhia V, Suominen P, Penttilä M:
Production of L-lactic acid by the yeast Candida sonorensis expressing
heterologous bacterial and fungal lactate dehydrogenases. Microb Cell
Fact 2013, 12:53.
21. Bio-Based News. http://bio-based.eu/news/commercial-production-worlds-
largest-scale-bio-succinic-acid-plant-2015.
22. Koopman F, Beekwilder J, Crimi B, van Houwelingen A, Hall RD, Bosch D,
van Maris AJ, Pronk JT, Daran JM: De novo production of the flavonoid
naringenin in engineered Saccharomyces cerevisiae. Microb Cell Fact 2012,
11:155.
23. Wang Y, Halls C, Zhang J, Matsuno M, Zhang Y, Yu O: Stepwise increase
of resveratrol biosynthesis in yeast Saccharomyces cerevisiae by
metabolic engineering. Metab Eng 2011, 13:455–463.
24. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell
MD, Tai A, Main A, Eng D, Polichuk DR, Teoh KH, Reed DW, Treynor T,
Lenihan J, Fleck M, Bajad S, Dang G, Dengrove D, Diola D, Dorin G, Ellens
KW, Fickes S, Galazzo J, Gaucher SP, Geistlinger T, Henry R, Hepp M, Horning
T, Iqbal T, Jiang H, Kizer L, Lieu B, Melis D, Moss N, Regentin R, Secrest S,
Tsuruta H, Vazquez R, Westblade LF, Xu L, Yu M, Zhang Y, Zhao L, Lievense
J, Covello PS, Keasling JD, Reiling KK, Renninger NS, Newman JD: High-level
semi-synthetic production of the potent antimalarial artemisinin. Nature
2013, 496:528–532.
25. Peralta-Yahya PP, Ouellet M, Chan R, Mukhopadhyay A, Keasling JD, Lee TS:
Identification and microbial production of a terpene-based advanced
biofuel. Nat Commun 2011, 2:483.
26. Ishiuchi K, Nakazawa T, Ookuma T, Sugimoto S, Sato M, Tsunematsu Y,
Ishikawa N, Noguchi H, Hotta K, Moriya H, Watanabe K: Establishing a new
methodology for genome mining and biosynthesis of polyketides and
peptides through yeast molecular genetics. Chembiochem 2012, 13:846–854.
27. Gao L, Cai M, Shen W, Xiao S, Zhou X, Zhang Y: Engineered fungal
polyketide biosynthesis in Pichia pastoris: a potential excellent host for
polyketide production. Microb Cell Fact 2013, 12:77.
28. Rugbjerg P, Naesby M, Mortensen UH, Frandsen RJ: Reconstruction of the
biosynthetic pathway for the core fungal polyketide scaffold
rubrofusarin in Saccharomyces cerevisiae. Microb Cell Fact 2013, 12:31.
29. Gidijala L, Kiel JA, Douma RD, Seifar RM, van Gulik WM, Bovenberg RA,
Veenhuis M, van der Klei IJ: An engineered yeast efficiently secreting
penicillin. PLoS One 2009, 4:e8317.
30. Hitzeman RA, Hagie FE, Levine HL, Goeddel DV, Ammerer G, Hall BD: Expression
of a human gene for interferon in yeast. Nature 1981, 293:717–722.
31. Mattanovich D, Branduardi P, Dato L, Gasser B, Sauer M, Porro D: Recombinant
protein production in yeasts. Methods Mol Biol 2012, 824:329–358.
32. Dragosits M, Frascotti G, Bernard-Granger L, Vázquez F, Giuliani M, Baumann
K, Rodríguez-Carmona E, Tokkanen J, Parrilli E, Wiebe MG, Kunert R, Maurer
M, Gasser B, Sauer M, Branduardi P, Pakula T, Saloheimo M, Penttilä M, Ferrer
P, Luisa Tutino M, Villaverde A, Porro D, Mattanovich D: Influence of growth
temperature on the production of antibody Fab fragments in different
microbes: a host comparative analysis. Biotechnol Prog. 2011, 27:38–46.
33. Mack M, Wannemacher M, Hobl B, Pietschmann P, Hock B: Comparison of
two expression platforms in respect to protein yield and quality: Pichia
pastoris versus Pichia angusta. Protein Expr Purif 2009, 66:165–171.
34. Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A:
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact
2009, 8:17.
35. Delic M, Göngrich R, Mattanovich D, Gasser B: Engineering of protein
folding and secretion - strategies to overcome bottlenecks for efficient
production of recombinant proteins. Antioxid Redox Signal 2014. [Epub
ahead of print] doi:10.1089/ars.2014.5844.
Mattanovich et al. Microbial Cell Factories 2014, 13:34 Page 4 of 5
http://www.microbialcellfactories.com/content/13/1/34
36. Delic M, Valli M, Graf AB, Pfeffer M, Mattanovich D, Gasser B: The secretory
pathway: exploring yeast diversity. FEMS Microbiol Rev 2013, 37:872–914.
37. Idiris A, Tohda H, Kumagai H, Takegawa K: Engineering of protein
secretion in yeast: strategies and impact on protein production.
Appl Microbiol Biotechnol 2010, 86:403–17.
38. Damasceno LM, Huang CJ, Batt CA: Protein secretion in Pichia pastoris and
advances in protein production. Appl Microbiol Biotechnol 2012, 93:31–9.
39. Hou J, Tyo KE, Liu Z, Petranovic D, Nielsen J: Metabolic engineering of
recombinant protein secretion by Saccharomyces cerevisiae. FEMS Yeast
Res 2012, 12:491–510.
40. Maccani A, Landes N, Stadlmayr G, Maresch D, Leitner C, Maurer M, Gasser B,
Ernst W, Kunert R, Mattanovich D: Pichia pastoris secretes recombinant
proteins less efficiently than Chinese hamster ovary cells but allows higher
space-time yields for less complex proteins. Biotechnol J 2014. [Epub ahead
of print] doi: 10.1002/biot.201300305.
41. Graf A, Dragosits M, Gasser B, Mattanovich D: Yeast systems biotechnology
for the production of heterologous proteins. FEMS Yeast Res 2009, 9:335–48.
42. Vanz AL, Lünsdorf H, Adnan A, Nimtz M, Gurramkonda C, Khanna N, Rinas U:
Physiological response of Pichia pastoris GS115 to methanol-induced high
level production of the Hepatitis B surface antigen: catabolic adaptation,
stress responses, and autophagic processes. Microb Cell Fact 2012, 11:103.
43. Jordà J, Jouhten P, Cámara E, Maaheimo H, Albiol J, Ferrer P: Metabolic flux
profiling of recombinant protein secreting Pichia pastoris growing on
glucose:methanol mixtures. Microb Cell Fact 2012, 11:57.
44. Klein T, Lange S, Wilhelm N, Bureik M, Yang TH, Heinzle E, Schneider K:
Overcoming the metabolic burden of protein secretion in
Schizosaccharomyces pombe - A quantitative approach using (13)C-based
metabolic flux analysis. Metab Eng 2014, 21:34–45.
45. Carnicer M, Ten Pierick A, van Dam J, Heijnen JJ, Albiol J, van Gulik W,
Ferrer P: Quantitative metabolomics analysis of amino acid metabolism
in recombinant Pichia pastoris under different oxygen availability
conditions. Microb Cell Fact 2012, 11:83.
46. Heyland J, Fu J, Blank LM, Schmid A: Carbon metabolism limits recombinant
protein production in Pichia pastoris. Biotechnol Bioeng 2011, 108:1942–53.
47. Liu L, Martínez JL, Liu Z, Petranovic D, Nielsen J: Balanced globin protein
expression and heme biosynthesis improve production of human
hemoglobin in Saccharomyces cerevisiae. Metab Eng 2014, 21:9–16.
48. Abad S, Nahalka J, Bergler G, Arnold SA, Speight R, Fotheringham I,
Nidetzky B, Glieder A: Stepwise engineering of a Pichia pastoris D-amino
acid oxidase whole cell catalyst. Microb Cell Fact 2010, 9:24.
49. Braun A, Geier M, Bühler B, Schmid A, Mauersberger S, Glieder A: Steroid
biotransformations in biphasic systems with Yarrowia lipolytica expressing
human liver cytochrome P450 genes. Microb Cell Fact 2012, 11:106.
50. Kratzer R, Egger S, Nidetzky B: Integration of enzyme, strain and reaction
engineering to overcome limitations of baker’s yeast in the asymmetric
reduction of alpha-keto esters. Biotechnol Bioeng 2008, 101:1094–101.
51. Wanarska M, Kur J: A method for the production of D-tagatose using a
recombinant Pichia pastoris strain secreting β-D-galactosidase from
Arthrobacter chlorophenolicus and a recombinant L-arabinose isomerase
from Arthrobacter sp. 22c. Microb Cell Fact 2012, 11:113.
52. Hama S, Yoshida A, Nakashima K, Noda H, Fukuda H, Kondo A: Surfactant-
modified yeast whole-cell biocatalyst displaying lipase on cell surface for
enzymatic production of structured lipids in organic media. Appl
Microbiol Biotechnol 2010, 87:537–43.
53. Yeast biotechnology. www.microbialcellfactories.com/series/Yeast
Biotechnology.
doi:10.1186/1475-2859-13-34
Cite this article as: Mattanovich et al.: Yeast biotechnology: teaching the
old dog new tricks. Microbial Cell Factories 2014 13:34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mattanovich et al. Microbial Cell Factories 2014, 13:34 Page 5 of 5
http://www.microbialcellfactories.com/content/13/1/34
